Of note, intracranial administration of CAR T cells targeting interleukin-13 receptor alpha 2 (IL-13Rα2) resulted in robust antitumor immunity and complete tumor regression in one patient with recurrent multifocal glioblastoma, which sustained for 7.5 mo following CAR T cell infusions [34]. The gene discussed is IL13RA2; the disease is neoplasm.